Bellevue, Wash.-based Overlake Hospital Medical Center was downgraded on a series of bonds as the 310-bed hospital faces ongoing labor and inflationary challenges and the possibility of not meeting its debt coverage requirements, Moody’s said March 9.
Little Rock-based Arkansas Health Network recently became the first clinically integrated network to attain dual accreditation from URAC in clinical integration and employer-based population health. Now it wants to be a model for others.
Springfield, Mass.-based Baystate Health had various ratings affirmed at “A+” as it continues to enjoy strong market share and a robust balance sheet despite recent operating losses, Fitch Ratings said March 10.
A burnout crisis has emerged among physicians that has widespread implications for clinicians and patients alike, Jack Resneck Jr., MD, American Medical Association president, wrote in an article March 9 on the organization’s website. He added that cha…
The Washington Senate approved a bill to raise Astria Toppenish (Wash.) Hospital’s Medicaid inpatient service reimbursement rates to 120 percent of the Medicaid fee schedule and outpatient reimbursement rates to 200 percent.
The CDC recently updated its recommendations for hepatitis B infection testing, saying all adults should be tested at least once in their lifetime and a wider range should be periodically retested.
Michael Wiggins was selected as the new president of Austin, Texas-based Dell Children’s, part of St. Louis-based Ascension’s Texas operations.
Federal investigators indicted the former CEO of a medical device company on March 9 in connection to a scheme that involved creating and selling a “non-functioning dummy” device that was implanted in patients with chronic pain, according to the Justic…
New York Gov. Kathy Hochul and Attorney General Letitia James asked CVS, Walgreens and Rite Aid to promise they will sell the abortion medication mifepristone as other state attorneys general work to block the drug’s distribution.
Life sciences company Merck has seen an improvement in pulmonary arterial hypertension patients using its new signaling inhibitor sotatercept in a phase three clinical trial.
